Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 17/20 | 0.45 |
| ▸ | SCN8A | Q9UQD0 | 2/20 | 0.40 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10297702 | 0.91 | GCK (0.43) | GCKSCN8ASCN10A | |
| SCHEMBL12089407 | 0.89 | GCK (0.45) | GCK | |
| SCHEMBL10297701 | 0.83 | GCK (0.40) | GCKSCN8ASCN10A | |
| SCHEMBL10297619 | 0.82 | GCK (0.40) | GCKSCN8ASCN10A | |
| SCHEMBL12088925 | 0.80 | GCK (0.45) | GCK | |
| SCHEMBL3598741 | 0.77 | GCK (0.57) | GCK | |
| SCHEMBL13403978 | 0.77 | GCK (0.48) | GCKSCN8ASCN10AHTR2AHTR2C | |
| SCHEMBL10297763 | 0.76 | GCK (0.42) | GCKSCN8ASCN10AHTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL3599999 | 0.76 | GCK (0.47) | GCKSCN8ASCN10AHTR2AHTR2C | |
| SCHEMBL22148 | 0.75 | GCK (0.41) | GCKSCN8ASCN10AHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8212045-B2 | Pyridin-2-yl-amino-1, 2, 4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus | ARRAY BIOPHARMA, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-20100204240-A1 | Pyridin-2-YL-Amino-1, 2, 4-Thiadiazole Derivatives as Glucokinase Activators for the Treatment of Diabetes Mellitus | ARRAY BIOPHARMA INC. (US) | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204240-A1 | Pyridin-2-YL-Amino-1, 2, 4-Thiadiazole Derivatives as Glucokinase Activators for the Treatment of Diabetes Mellitus | PDXK, GCKR, GCK | GCK 3/4885SCN8A 4486/4885SCN10A 4752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.